Parabilis Medicines, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Parabilis Medicines, Inc. announced its intention to present updated clinical data for zolucatetide in desmoid tumor patients at the ESMO Congress 2026.
NASDAQ
Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., an accomplished drug development leader with extensive oncology experience, to its Board of Directors.
NASDAQ
Parabilis Medicines announced strong Q2 2026 results, highlighting advancements in zolucatetide trials, a major collaboration with Regeneron, and a robust cash position extending runway to 2030.